AstraZeneca tightens focus

Thursday 10 November 2016
Country

United Kingdom

AstraZeneca Plc is accelerating development of its oncology portfolio and tightening its therapeutic focus with an eye to returning to growth by 2018, or possibly earlier. The company’s third quarter results, released on 10 November, showed group revenue down by 4% to $5.7 billion, but new therapies in oncology and diabetes posted stronger sales.